Provenge
(Sipuleucel-T)Phase 3Cell therapy
Sipuleucel-T is used to treat advanced prostate cancer in men whose cancer no longer responds to hormone therapy. It works by boosting the patient's own immune system to fight the cancer cells.[1] Provenge is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Provenge is one of 31 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
33
Total Trials
6
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Antiandrogen Therapy
UUniversity of Washington
Phase 3
Provenge
PProstate Oncology Specialists, Inc.
Phase 3
Triptorelin Embonate
IpsenPhase 3
Lhrha
Johnson & JohnsonPhase 3
Docetaxel /m²
AstraZenecaPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer21 trials
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting·—·Phase 1·NCT07219147·30 enrolled
Show 18 more trials
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Completed·—·Phase 1·NCT02036918·20 enrolled
Metastatic Prostate Cancer6 trials
Show 3 more trials
Concentration1 trial
mCRPC1 trial
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02463799·36 enrolled
3 more indications
Metastatic Castration-Resistant Prostate Cancer1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sipuleucel-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details